CARDIFF ONCOLOGY, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
CARDIFF ONCOLOGY, INC. (CRDF) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $1.00 million for the 12-month period ending 2020-12-31, per its 10-K filed 2022-02-24.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2022-02-24
- CARDIFF ONCOLOGY, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2020 was $1.00M.
- CARDIFF ONCOLOGY, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2019 was $0.00.
- CARDIFF ONCOLOGY, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2017 was $0.00, a 100.00% decline from fiscal 2016.
- CARDIFF ONCOLOGY, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2016 was $1.93M, a 39.83% increase from fiscal 2015.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|
| 2020-12-31 | $1.00M 10-K · filed 2022-02-24 |
| 2019-12-31 | $0.00 10-K · filed 2021-02-25 |
| 2017-12-31 | $0.00 10-K · filed 2018-02-26 |
| 2016-12-31 | $1.93M 10-K · filed 2018-02-26 |
| 2015-12-31 | $1.38M 10-K · filed 2017-03-15 |
| 2014-12-31 | $0.00 10-K · filed 2017-03-15 |
| 2013-12-31 | $275.49K 10-K · filed 2016-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B |